Last reviewed · How we verify
S1904 CD19 CAR-T
At a glance
| Generic name | S1904 CD19 CAR-T |
|---|---|
| Sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL (PHASE2)
- Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |